Which are the main transformations Dos Ni Roha has undergone in recent years? Dos Ni Roha has successfully taken advantage of its wide expertise in the…
In Conversation
Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities…
Please introduce the Korean Food and Drug Administration (KFDA) and its main health-related responsibilities within the Korean government… The KFDA’s main duty is to cooperate and…
APL is part of Zuellig, the top Asian pharmaceutical distributor. How does being part of a large, regionally specialized player help APL here in Indonesia? Being…
How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since…
You have a very long track record working with Novo Nordisk in Asia. What is your perspective on the Diabetes explosion that has been taking place…
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the…
Many multinational companies have chosen to forgo establishing production facilities in Indonesia or have even shuttered their facilities, as did Janssen-Cilag. With the recent 10/10 decree,…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes…
Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing…
The Indonesian pharmaceutical market has gone through a series of developing phases which have ultimately led the domestic industry to gain the majority of the market…
